Compounded Semaglutide vs Ozempic: Mechanism, FDA Status, Evidence

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with the manufacturers reviewed.

Compounded Semaglutide and Ozempic are frequently compared by patients and providers evaluating weight-management options as of April 2026. They differ on FDA-approval status, formulation, pharmacology, regulatory pathway, evidence base, and pricing — each of which shapes the clinical and practical decision. This article reviews each compound side-by-side, then surfaces the upstream genetic variable that no specific compound addresses on its own.

What Compounded Semaglutide is

Compounded Semaglutide is a GLP-1 receptor agonist produced by licensed 503A compounding pharmacies. Regulatory status: not FDA-approved as a branded product; available through licensed compounding pharmacies for individual patient prescriptions. The compound's pharmacology and clinical positioning derive from the underlying GLP-1 pathway biology — appetite regulation, satiety signaling, gastric emptying, and post-meal glucose excursion modulation.

What Ozempic is

Ozempic is a GLP-1 receptor agonist produced by Novo Nordisk. Regulatory status: FDA-approved for type 2 diabetes (2017); also approved for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Pharmacology mirrors the underlying GLP-1 pathway biology — the same receptor target as the compounded counterpart.

Side-by-side: regulatory status and formulation

The core regulatory difference is straightforward. Ozempic is an FDA-approved branded product manufactured under cGMP (current Good Manufacturing Practice) standards by Novo Nordisk, with full clinical-trial data submitted to FDA. Compounded Semaglutide is dispensed through licensed 503A compounding pharmacies under individual patient prescriptions — the compounding pathway is regulated by state pharmacy boards and the FDA but does not require pre-market approval as a branded product. Compounded products are legally and factually distinct from FDA-approved brand products; they are not "generics" and are not bioequivalent in the regulatory sense.

For patients, this means: when an FDA shortage of the brand exists (semaglutide was in shortage 2022-2024; tirzepatide 2022-early 2025), 503A pharmacies could legally compound the molecule for individual patient prescriptions. After shortage resolution, the legal compounding pathway narrowed but did not close — patient-specific clinical justification remains a permissible compounding rationale under federal law.

Evidence base

Clinical evidence on Compounded Semaglutide as a compound is limited compared to Ozempic's extensive Phase 3 trial program (STEP for semaglutide weight management, SUSTAIN for diabetes; SURMOUNT for tirzepatide weight management, SURPASS for diabetes — all published in The New England Journal of Medicine, 2021-2024). Compounded formulations do not undergo the same trial process. The pharmacological mechanism is identical — the underlying molecule is the same — but compounded-product-specific dosing, vehicle, and formulation can vary by pharmacy. Clinical efficacy data is therefore extrapolated from the brand evidence rather than directly demonstrated for the compounded version.

Side effects and safety profile

Compounded Semaglutide and Ozempic have distinct safety profiles. GLP-1 receptor agonists in either form share the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Common side effects across the class are gastrointestinal (nausea, vomiting, diarrhea, constipation), most pronounced during dose escalation. Compounded products may have additional pharmacy-specific quality and sterility considerations — verifying that the dispensing pharmacy is state-licensed, USP <797> compliant for sterile compounds, and that the prescribing provider conducts a clinical evaluation are critical.

Cost and access

Ozempic list price is approximately $968-$1,349 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). Out-of-pocket cost depends on insurance coverage, the FDA-approved indication on the prescription, and manufacturer savings card eligibility. Compounded Semaglutide is dispensed through licensed compounding pharmacies at separate price points, often substantially below the brand list price. PlexusDx publishes per-protocol pricing on its Semaglutide Injection product page.

The genetic variable underneath every GLP-1 decision

Whichever compound a patient and provider choose, the upstream genetic architecture is shared. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor itself), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (a transcription factor linked to glucose homeostasis) shape baseline appetite regulation, satiety signaling, and the metabolic terrain on which any GLP-1 protocol operates. These variants are pathway-level — they don't predict response to any specific compound, but they describe the biology a clinician is prescribing into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Over The Counter Ozempic, Ozempic Drug, Ozempic Uses, Novo Nordisk Ozempic.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context most providers don't offer. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Is Compounded Semaglutide the same as Ozempic?

No. Compounded Semaglutide is dispensed through licensed compounding pharmacies as a patient-specific prescription; Ozempic is an FDA-approved branded product. The active molecule is the same chemical substance, but the products are legally and factually distinct. Compounded products are not "generics" and not bioequivalent in the regulatory sense.

Is Compounded Semaglutide legal?

Yes, when dispensed through a licensed 503A compounding pharmacy under a valid prescriber order. Federal law allows compounding under specific pathways including patient-specific prescriptions, FDA-declared shortages, and clinically-justified individual variations. Verify the dispensing pharmacy is state-licensed before any commitment.

Does the Precision Peptide Genetic Test predict Compounded Semaglutide response?

No. The Precision Peptide Genetic Test does not predict response to any specific compound or formulation. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 — the upstream context that applies regardless of which compound or formulation a clinician prescribes.

Which costs less, Compounded Semaglutide or Ozempic?

Compounded Semaglutide typically costs less per month than Ozempic at U.S. list price. Actual out-of-pocket cost depends on insurance coverage, savings programs, the FDA indication on the prescription, and the specific compounding pharmacy or telehealth program. Verify current pricing on the relevant product page before any commitment.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education